Antiangiogenesis, heralded a while ago as the "magic bullet" to stop cancer growth, has lately entered a reconsideration phase. Results obtained in phase 1 through 3 clinical trials with different ...

Judah Folkman found himself in that position as his two big antiangiogenesis drugs, endostatin and angiostatin, finally headed toward clinical trials near the end of 1999. Folkman was expected to ...